导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.66% | 3800/4773 |
| 近一周 | -1.93% | 905/5462 |
| 近一月 | -0.60% | 799/5421 |
| 近一季 | 3.81% | 344/5209 |
| 近半年 | -8.73% | 3390/4920 |
| 近一年 | -14.60% | 3652/4366 |
| 近两年 | 8.24% | 2819/2954 |
| 近三年 | -9.84% | 2029/2253 |
| 成立以来 | 13.28% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-5.13% 3768/4961 |
-13.28% 4485/5312 |
- - |
- - |
| 2025 | 0.10% 3285/4813 |
-0.34% 2208/3635 |
-2.99% 3401/4076 |
5.93% 3561/4524 |
-2.26% 3111/4813 |
| 2024 | 7.84% 1613/3463 |
4.91% 419/2808 |
-5.31% 1688/3014 |
14.86% 1892/3129 |
-5.49% 2566/3463 |
| 2023 | -15.35% 1647/2656 |
1.82% 1506/2280 |
-9.83% 2075/2385 |
-2.30% 658/2515 |
-5.64% 1439/2655 |
| 2022 | -15.76% 431/2207 |
-18.75% 1389/1919 |
16.38% 153/2016 |
-11.73% 571/2113 |
0.92% 1428/2208 |
| 2021 | -6.19% 1000/1822 |
-3.95% 837/1255 |
5.42% 810/1330 |
-10.62% 1231/1466 |
3.66% 409/1822 |
| 2020 | - - |
- - |
- - |
16.64% 141/1164 |
21.45% 54/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 东兴中证消费50C VS. 长安沪深300非周期A(740101) |